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Abstract
Background: In adults it is well documented that there are substantial losses to the programme between HIV testing and
start of antiretroviral therapy (ART). The magnitude and reasons for loss to follow-up and death between HIV diagnosis and
start of ART in children are not well defined.
Methods: We searched the PubMed and EMBASE databases for studies on children followed between HIV diagnosis and
start of ART in low-income settings. We examined the proportion of children with a CD4 cell count/percentage after after
being diagnosed with HIV infection, the number of treatment-eligible children starting ART and predictors of loss to
programme. Data were extracted in duplicate.
Results: Eight studies from sub-Saharan Africa and two studies from Asia with a total of 10,741 children were included.
Median age ranged from 2.2 to 6.5 years. Between 78.0 and 97.0% of HIV-infected children subsequently had a CD4 cell
count/percentage measured, 63.2 to 90.7% of children with an eligibility assessment met the eligibility criteria for the
particular setting and time and 39.5 to 99.4% of the eligible children started ART. Three studies reported an association
between low CD4 count/percentage and ART initiation while no association was reported for gender. Only two studies
reported on pre-ART mortality and found rates of 13 and 6 per 100 person-years.
Conclusion: Most children who presented for HIV care met eligibility criteria for ART. There is an urgent need for strategies
to improve the access to and retention to care of HIV-infected children in resource-limited settings.
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Introduction
In 2010 worldwide about 3.4 million children younger than 15
years were HIV infected, of whom over 90% lived in sub-Saharan
Africa [1]. In low-income countries, more than half of vertically-
infected children die before the age of two years if they remain
untreated [2]. Although early antiretroviral therapy (ART) has
been shown to dramatically reduce early mortality and progression
of HIV [3], the estimated coverage of ART in low and middle
income countries is still much lower in children than in adults: in
2010 23% of the children in need of therapy received ART
compared to 51% of adults [1]. However, the reasons for poor
uptake of HIV testing and low therapy coverage in children are
poorly understood.
A major challenge of health care programmes in the context of
the rapid scale-up of ART is to retain patients in care after they
tested positive for HIV. Retention is particularly poor in patients
not yet eligible for ART. A recent systematic review in adults
showed that only 59% of HIV positive patients had a CD4 count
to determine treatment eligibility and that only 68% of ART
eligible patients started ART [4]. Higher pre-ART retention in
adults was associated with the availability of a point-of-care CD4
test [5,6] and a better health status of the patient [7]. There are
few data on loss to programme (mortality, loss to follow-up and
transfer out) between HIV testing and start of ART in children.
Good retention in care in children may be associated with similar
factors as in adults but will in addition depend on the caregiver.
We performed a systematic review to estimate the magnitude
and reasons for loss to programme between HIV testing and start
of ART in HIV infected children in low-income settings.
Materials and Methods
Data sources
We searched the PubMed and EMBASE bibliographic data-
bases on August 9, 2011. We limited the search to English-
language publications which reported on patients in low-income
settings. We further limited the search to studies published from
2002 onwards because the scale-up of ART in resource-limited
settings (as defined by the World Bank classification) happened
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after 2002 [8,9]. We used both free text and Medical Subject
Headings (MeSH) and used a combination of the following words
and their variations: ‘antiretroviral agents’, ‘therapeutic use’, ‘pre
treatment’, ‘pre-ART’, ‘prior to treatment’, ‘eligibility’, ‘loss to
care’ and ‘loss to follow-up’. We examined the references of all
included studies. Further details of the search strategy are shown in
the Appendix S1.
Study selection
We included all studies that reported on numbers of children
followed between HIV diagnosis and start of ART, including
studies that did not cover the entire time period. We excluded
studies on adults and on the prevention of mother-to-child
transmission (PMTCT). We also excluded qualitative studies, data
from clinical trials and reports from national programmes (as there
was a risk of duplicated data and lack of detailed information).
Articles were excluded if they reported on the same study
population and time period as another article that was more
complete. Two reviewers (C.M., O.K.) assessed the eligibility of
articles and abstracts. Discrepancies were resolved by consensus
between the two reviewers.
Data extraction and analysis
We extracted the data of each publication in duplicate using a
standardised data extraction sheet. The following information was
extracted for each study: inclusion criteria, characteristics of the
programme (setting, location, country), characteristics of the
children (age, gender, CD4 cell counts or percentages at different
time points), eligibility criteria for ART initiation and methods for
tracing children lost to follow-up. In addition we extracted the
Figure 1. Identification and selection of studies. ART: Antiretroviral therapy; RCT: Randomized controlled trial; PMTCT: Prevention of mother to
child transmission.
doi:10.1371/journal.pone.0056446.g001
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number of children alive or lost to programme (i.e. lost to follow-
up, transferred-out or died) during different time periods. The
following time points were of interest: HIV testing, CD4 testing or
clinical staging with eligibility assessment for ART, becoming
eligible for ART and start of ART. We also assessed the number of
children staying in pre-ART care and overall losses to programme
and mortality before ART initiation or during pre-ART care.
Finally we extracted predictors for loss to programme, mortality
and loss to follow-up between HIV testing and CD4 testing and
between meeting eligibility criteria for ART and ART initiation.
We recorded if there was a positive or negative statistically
significant association (p,0.05) or if there was no statistically
significant association (p$0.05). Discrepancies were resolved by
consensus. Data were entered into an EpiData database (version
3.1). We calculated the percentage of children completing each
time step and displayed the results as forest plots. Data were
analysed using STATA version 11.2 (StataCorp, Texas, USA).
Results
Study characteristics
We identified 1,656 potentially relevant articles (Figure 1). Ten
studies were included in the systematic review (Table 1): eight
studies from sub-Saharan Africa (one study each from Coˆte
d’Ivoire, the Democratic Republic of Congo, Ethiopia, Lesotho,
Malawi, South Africa, Zambia and Kenya); one study from India;
one study from Cambodia. The studies contributed data on
10,741 children and included all children who attended routine
clinics during a specified time period, except for one study [10], in
which a random sample of children was analyzed. Most of the
studies were multi-site (n = 8); two studies were conducted at one
site. The majority of studies reported on programmes in urban
clinics where patients were seen by medical doctors. Table 1 shows
a detailed description of the programmes studied, including the
level of care delivery and the funding sources for the study. The
median age of the children ranged from 2.2 to 6.5 years. Median
or mean CD4 cell count at presentation ranged from 385 to 622
cells/ml, and median CD4 percentage from 14.5% to 16%. A
detailed listing of CD4 cell measurement at presentation and
corresponding age group in the study can be found in Table 1.
Mortality, loss to follow-up and transfer out
Deaths among patients lost to follow-up were ascertained in 5
studies by phone calls or home visits. Two studies reported on pre-
ART mortality and found rates of 13.0 [11] and 6.0 [12] per 100
person-years (Table S1). A loss to follow-up rate and transfer-out
rate before ART initiation were reported by one study [11] and
were 50.3 and 2.9 per 100 person-years respectively. Four studies
reported on percentages of children who died, were lost to follow-
up/defaulted or transferred out before starting ART [13–16], and
one study reported the proportion of patients lost to follow-up
[17]. A small study of 24 children reported on the proportion of
children who died, with no children lost to follow-up [18]. The
estimates ranged between 3.2% and 45.8% for mortality, 0.0%
and 37% for loss to follow-up and 3.4% and 4.6% for transfer out
(Table S1). Since the person-time at risk was not reported these
percentages are difficult to interpret.
Pre ART cascade
Studies reporting at least one of the three steps (HIV diagnosis
to CD4 cell determination, ART eligibility assessment to meeting
eligibility criteria, meeting ART eligibility criteria to ART start)
were included in this analysis.n
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From HIV diagnosis to CD4 cell determination
Four studies [11,13,15,17] reported on the step from HIV
diagnosis to CD4 cell measurement. The percentage of children
with a CD4 cell count ranged from 78.0% to 97.0% (Figure 2,
panel A).
From assessment of eligibility to start of ART
Four studies [10,11,13,19] reported on the period from
assessment of eligibility to start of ART. The percentage of
children diagnosed with HIV who had a CD4 cell count/
percentage measured and were eligible for ART ranged from
63.2% to 88.7% (Figure 2, panel B). Five studies [10,11,13,15,19]
reported on the number of children starting ART after meeting
eligibility criteria. Estimates ranged from 39.5% to 99.4%
(Figure 2, panel C).
Predictors of mortality, loss to follow-up and ART
initiation
Three studies reported on predictors for starting ART while no
study reported on predictors for determining a CD4 cell count/
percentage or of mortality. A low CD4 cell count was a strong
predictor for ART initiation in all three studies [10,12,15]. Two
studies reported no association between gender and ART
initiation. Sutcliffe et al [15] reported that a long distance to the
clinic was associated with loss to follow-up (in particular in
children living in rural areas) and Edmonds et al [12] found that
advanced clinical stage was associated with ART initiation.
Discussion
Our systematic review included over 10,000 children from 10
low-income countries. In general, few data were available on the
different outcomes and heterogeneity across studies was substan-
tial. Our analysis showed that in low-income settings, 78% and
97% of HIV-infected children had a CD4 count/percentage
measured and that the large majority of these patients met ART
eligibility criteria at presentation. Among those who were assessed
for ART eligibility, 63% to 91% of the children were already
eligible for therapy, and of the eligible children 40% to 99%
initiated ART. According to the WHO 2006 guidelines [20], most
children in WHO stage 3 (with few exceptions) and all children in
WHO stage 4 are eligible for ART irrespective of CD4 count or
percentage, and children in WHO stage 1 and 2 are eligible if the
CD4 percentage or absolute CD4 cell count is below an age-
specific threshold. In the 2010 revision of the guidelines, WHO
recommended that all children aged ,2 years should start ART
irrespective of the CD4 count, percentage or clinical stage [21].
Different eligibility criteria will influence the number of people
deemed eligible for ART initiation while for children in advanced
clinical stage it was not necessary to measure CD4 cells. Apart
from two studies [12,18] the follow-up ended before the new
guidelines were published. Our study could thus not determine the
impact of the change in guidelines on retention in care.
Furthermore, operational and financial barriers were the source
of differences between implementations of the new ART
guidelines across countries. During the study period other major
operational changes were made. This includes, for example scale-
up of access to PCR HIV testing for children ,18 months and use
of paediatric syrups instead of soluble fixed dose combinations.
This further limited comparison of treatment uptake overall, and
for specific age groups and time periods in particular.
This systematic review has several other limitations: 1) The
search strategy was limited to English-language publications from
only two databases. 2) The generalizability of our findings was
influenced by the geographic limitations of the search and the
small number of studies. 3) Many studies did not explicitly report if
the CD4 cell count used to determine treatment eligibility was the
first measured CD4 cell count or if the measurement was taken
during pre ART care. 4) The studies did not limit the analysis of
predictors for ART initiation to ART eligible children only. 5)
Only few studies reported on the outcomes of children not
retained in care, as these were not traced systematically in most
studies. 6) Finally, it was not always possible to distinguish between
overall loss to programme and loss to follow-up if mortality and
transfer out was not reported. No study reported on all outcomes
and on predictors influencing these outcomes, which made it
impossible to assess exactly what happened to these children and
why they were lost from follow-up.
Presentation for HIV testing and treatment at a late stage of
disease has been shown to increase mortality both before and after
ART initiation [22–24]. It also increases the risk of developing
infectious and non-infectious diseases in HIV-infected children
[25]. In this study, we found that the large majority of children
were eligible for ART at first presentation. This finding reflects the
general failure of health systems to diagnose paediatric HIV-
infections and enrol these patients into HIV care early in the
course of the disease. Limited capacity to perform PCR testing in
infants and to retrieve test results remain important barriers to the
success of many ART programmes. Also the lack of integration of
Figure 2. Forest plots – time from HIV diagnosis to start of
antiretroviral therapy (ART). A): Percentage of HIV positive children
with a CD4 cell count/percentage. B): Percentage of children with an
eligibility assessement who meet eligibility criteria for ART. C):
Percentage of ART eligible children starting ART.
doi:10.1371/journal.pone.0056446.g002
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[26], stigma, and other socio-cultural barriers are major problems.
In a previous meta-analysis, we found that 64% of HIV-exposed
infants received early infant diagnosis by PCR at around 6 weeks,
and 55% were tested between 12–18 months [27].
Detailed reasons for poor uptake of HIV testing and treatment
in low income settings remain poorly understood. No studies
included in this review differentiated loss to follow-up in children
tested by PCR versus those tested with rapid tests. The feasibility
and effect of decentralization of paediatric HIV care could also not
be assessed. Since studies evaluating PMTCT programme
outcomes were excluded from the analysis, one of the reasons
for the high proportion of children with advanced clinical disease
at presentation could be that the majority of these children were
not included in ART programmes after birth.
Several studies, including two systematic reviews [4,28], have
shown that about one third of adult patients who meet ART
eligibility criteria never started ART. In the present study we found
that the situation is more encouraging for children since 40% to
99% of treatment eligible children started ART. Table 2 compares
the present review with the two previous systematic reviews in
adults. Most importantly, more treatment-eligible children than
adults start ART. In Rosen et al [4], fewer patients were assessed for
eligibility but the definition of this second step differed slightly.
Not surprisingly low CD4 cell counts and advanced clinical stage
of disease were important predictors for starting ART. However,
the high proportion of children starting ART in advanced clinical
stage could also mean that these children are more likely to access
and remain in HIV care whereas healthier children might not be
linked to ART programmes or may drop out during follow-up. In
rural areas time from diagnosis to ART initiation was longer if the
distance to the clinic increased [15]. Structural barriers for retention
in HIV care have been described in adults [4] and the same factors
also influence clinical outcomes in children.
Our findings underline the need to improve linkage to care and
access to ART for HIV-infected children in low-income countries. A
wide range of measures and interventions have been proposed to
improve clinical outcomes of these patients. These include more widely
available point-of-care CD4 cell count testing [5,6] and removal of
barriers to ART in specific populations. The WHO 2010 guidelines
that recommend ART for all children,2 years old, regardless of CD4
cell count/percentage [21] are one example. Other approaches to
improve retention in PMTCT programmes (e.g. staff training and
active defaulter tracing systems [29,30]) and access to general health
care programmes, such as family-centred models [31] have also been
proposed. In order to increase the coverage of ART, especially in
remote rural settings, HIV testing and care have to be decentralized
and brought to the communities [32]. This is particularly important for
PCR diagnosis in infants ,18 months old.
In conclusion, this systematic review shows that the large majority
of children accessing HIV care meet ART eligibility criteria,
suggesting that efforts should be made to link children to HIV
testing and ART programmes at earlier stages. Pre-ART mortality
and loss to follow-up remain important barriers to the improvement
of ART coverage in HIV infected children in resource-limited
settings. Importantly, data on clinical outcomes and predictors of
retention in care during the pre-ART time period are scarce. Future
studies should document mortality, loss to follow-up and transfer-
out for all pre-ART time periods. HIV testing by PCR in children
less than 18 months should be distinguished from other HIV tests.
Assessment of eligibility criteria for starting ART should be
separated into immunological (absolute and percentage CD4) and
clinical criteria and stratified by age. Children lost to programme
should be traced and reasons for attrition recorded. Finally, future
studies should specifically examine whether universal ART for all
children less than two years (irrespective of CD4 cell determination)
decreases pre-ART loss to programme in these children.
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